Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

LOS ANGELES, CA / ACCESSWIRE / September 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Danaher Corporation ("Danaher" or "the Company") (NYSE:DHR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 21, 2022 and April 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 15, 2023.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Danaher Corporation with Losses of $100,000 to Contact the Firm

Lower demand for COVID-related products, raw material cost inflation and foreign currency headwinds weigh on Danaher's (DHR) operations.

Here's Why You Should Steer Clear of Danaher (DHR) Stock Now

LOS ANGELES, CA / ACCESSWIRE / September 5, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Danaher Corporation ("Danaher" or "the Company") (NYSE:DHR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 21, 2022 and April 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 15, 2023.

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Danaher Corporation with Losses of $100,000 to Contact the Firm

NEW YORK , Sept. 4, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Danaher Corporation (NYSE: DHR) between April 21, 2022 and April 24, 2023, both dates inclusive (the "Class Period"), of the important September 15, 2023 lead plaintiff deadline.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Danaher Corporation Investors with Losses to Secure Counsel Before Important September 15 Deadline in Securities Class Action - DHR

LOS ANGELS, CA / ACCESSWIRE / September 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Danaher Corporation ("Danaher" or "the Company") (NYSE:DHR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 21, 2022 and April 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 15, 2023.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Danaher Corporation with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Danaher Corporation ("Danaher" or "the Company") (NYSE:DHR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 21, 2022 and April 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 15, 2023.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Danaher Corporation with Losses of $500,000 to Contact the Firm

WASHINGTON , Aug. 31, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of Veralto's Investor and Analyst Meeting on September 6, 2023 beginning at approximately 12:00 p.m. CT. The event, which will provide a comprehensive overview of Veralto and its operating segments, will be held at Videojet's facility in Wood Dale, Illinois and hosted by Veralto President & CEO Jennifer L.

Danaher and Veralto to Webcast Investor and Analyst Meeting

Applied Materials

Dollar General

Dolby Laboratories

Equinix

Gilead Sciences

Garmin

Martin Marietta Materials

Monolithic Power Systems

M&T Bank

Norfolk Southern

Old Dominion Freight Line

SAP SE

Sony

Constellation Brands

Toronto-Dominion Bank

Thermo Fisher Scientific

TC Energy

Verisk Analytics

This article presents the highest-quality Dividend Challengers, companies listed on U.S. exchanges with consistently higher annual dividend payouts for 5-9 years. The top 20 highest-quality Dividend Challengers are identified based on a quality scoring system, with Toronto-Dominion Bank, Dolby Laboratories, and Thermo Fisher Scientific making the top three. The article also highlights stocks trading at favorable valuations and offering compelling metrics for income-focused, growth-oriented, value-driven, and total-return investors.

The Highest Quality Dividend Challenger Summary

Johnson & Johnson

Artificial Intelligence ( AI ) has received incredible attention this year due to the public release of OpenAI's  ChatGPT. Its profound capabilities have successfully captured the imaginations of a swath of audiences from technology enthusiasts and investors to social commentators.

When ChatGPT Misses the Mark: 3 Stocks It Got Very Wrong

Danaher Corporation benefited from the Covid-19 period and saw strong growth, aided by bolt-on deals and reasonable leverage. The company acquired the biopharma business from General Electric in a $21 billion deal, adding highly profitable sales. Despite strong results, the risk-reward for Danaher Corporation has deteriorated, as shares have recently recovered while 2023 performance so far has been weak.

Danaher: A Lost Year

Danaher (DHR) is set to acquire Abcam in a $5.7 billion deal, boosting its Life Sciences portfolio while solving some of the world's greatest healthcare challenges.

Danaher (DHR) to Acquire Abcam, Boost Life Sciences Unit

Abcam

Medical tool supplier Danaher (DHR) is expanding its product offerings by purchasing British biotech firm Abcam Plc (ABCM) for $5.7 billion, including debt.

Danaher Buys Abcam for $5.7 Billion to Expand Its Product Offerings

Danaher Corporation (NYSE: DHR) is in focus this morning after it revealed plans of buying Abcam PLC (NASDAQ: ABCM) for $5.70 billion in cash. Abcam shareholders are not happy The definitive agreement announced today values each share of the biotech firm at $24 – up only slightly from their previous close.

Danaher is buying Abcam PLC for $5.70 billion

Danaher (NYSE:DHR) said it will be acquiring UK-based biotechnology supplier Abcam (AIM:ABC) for $24 per share or a total enterprise value of about $5.7 billion. Danaher (NYSE:DHR) beat out rivals who were also bidding for the company including Agilent Technologies (NYSE:A), according to media reports.

Danaher acquires biotech supplier Abcam for $5.7B

Danaher Corp said on Monday it would buy smaller rival Abcam Plc in a deal valued at $5.7 billion including debt, as the medical tools supplier eyes bigger contracts by expanding its services.

Medical tech firm Danaher to buy Abcam in deal valued at $5.7 bln

The industrial scientific-supplies company agrees to acquire all shares outstanding for $24.00 each.

Danaher to Buy Abcam in $5.7 Billion Deal. Investors Don't Like the Premium.

Abcam Plc stock ABCM, +3.87% was up 0.4% in premarket trades Monday after it said it agreed to be acquired by Danaher Corp. DHR, +0.78% for $24 a share in cash in a deal that values the maker of antibodies and reagents for drug discovery efforts at about $5.7 billion including debt. The price amounts to a premium of 64 cents a share, or 2.7% over its closing price of $23.36 on Friday.

Abcam agrees to be acquired by Danaher in $5.7B deal

CAMBRIDGE, England & WALTHAM, Mass.--(BUSINESS WIRE)--Abcam plc (Nasdaq: ABCM) (‘Abcam', the ‘Group' or the ‘Company'), a global leader in the supply of life science research tools, announced today that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) (‘Danaher') will acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction').

Danaher to acquire Abcam for $24.00 per Share

WASHINGTON , Aug. 28, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Abcam plc (NASDAQ: ABCM), a leading global supplier of protein consumables, pursuant to which Danaher will acquire all of the outstanding shares of Abcam for $24.00 per share in cash, or a total enterprise value of approximately $5.7 billion including assumed indebtedness and net of acquired cash. Founded in 1998 and headquartered in Cambridge, UK, Abcam offers the scientific community highly validated antibodies, reagents, biomarkers and assays to address targets in biological pathways that are critical for advancing drug discovery, life sciences research, and diagnostics.

Danaher to Acquire Abcam

NEW YORK , Aug. 28, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Danaher Corporation (NYSE: DHR) alleging that the Company violated federal securities laws. Class Period: April 21, 2022 to April 24, 2023 Lead Plaintiff Deadline: September 15, 2023 No obligation or cost to you.

SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 15, 2023 in the Class Action Filed on Behalf of Danaher Corporation (DHR) Shareholders

NEW YORK , Aug. 25, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Danaher Corporation (NYSE: DHR) between April 21, 2022 and April 24, 2023, both dates inclusive (the "Class Period"), of the important September 15, 2023 lead plaintiff deadline. SO WHAT: If you purchased Danaher securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A RANKED AND LEADING FIRM, Encourages Danaher Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - DHR

WASHINGTON , Aug. 25, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced that it expects to complete the previously announced separation of Veralto Corporation on September 30, 2023, the first day of Danaher's fiscal fourth quarter. The Danaher Board of Directors has declared a pro rata dividend of all of the common stock of Veralto Corporation to Danaher stockholders of record as of the close of business on September 13, 2023 (the "Record Date").

Danaher Declares pro Rata Dividend of Veralto Common Stock and Announces Expected "When-issued" Trading of Veralto Common Stock

Danaher Corp is in the lead to acquire Abcam Plc , a provider of supplies to life science researchers with a market value of $5.1 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday.

Exclusive: Danaher in the lead to acquire biomedical equipment vendor Abcam-sources

LOS ANGELES, CA / ACCESSWIRE / August 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Danaher Corporation ("Danaher" or "the Company") (NYSE: DHR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 21, 2022 and April 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 15, 2023.

INVESTOR ACTION DEADLINE: The Schall Law Firm Encourages Investors in Danaher Corporation with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Danaher Corporation ("Danaher" or "the Company") (NYSE: DHR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 21, 2022 and April 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 15, 2023.

News for Danaher Stock (DHR)